DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation SAN DIEGO, Dec. 21, 2023 — DMK Pharmaceuticals Corporation (Nasdaq: DMK) (“DMK”), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, announces that it has regained the […]

DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update

Now seeking out license opportunities for SYMJEPI® SAN DIEGO, Nov. 28, 2023 — DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced that it is reacquiring the rights to its SYMJEPI® (epinephrine) Injection 0.3mg and […]

DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI® and thus increase shareholder value Developed holistic company growth strategy to create a cost effective, coordinated, streamlined approach to operations to increase value for patients and shareholders […]

DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023

SAN DIEGO, Nov. 13, 2023 — DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard […]

DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 20, 2023 — DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board of directors approved the grant of a stock option on October 16, 2023, to purchase an aggregate of 151,416 shares of common stock to Seth A. Cohen, a newly hired employee […]

DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth

Seth Cohen is appointed Chief Financial Officer, bringing over thirty years of financial industry experience to DMK, and seasoned corporate lawyer John Dorbin assumes role of General Counsel Corporate Secretary Appointments strengthen leadership team and provide financial and corporate expertise as the organization focuses on improving DMK’s existing commercial product portfolio and reducing opioid related […]

Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus

Company to begin trading under new ticker symbol “DMK” on September 8, 2023 SAN DIEGO, Sept. 07, 2023 — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment […]

Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 21, 2023 — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 Corporate Highlights In May, the Company closed the merger with DMK Pharmaceuticals Corporation (DMK), a private, clinical-stage biotechnology […]